FDA Reviewing Study Suggesting Pancreatitis, Pre-Cancer Risk From Incretin Diabetes Drugs

ROCKVILLE, Md. - The Food and Drug Administration on March 14 said it is evaluating an unpublished medical study that suggests an increased risk of pancreatitis and pre-cancerous cell changes in type 2 diabetics treated with incretin memetic drugs....(read more)Image may be NSFW.
Clik here to view.